Africa & Middle East

Visitors will explore the latest advancements to improve patient outcomes and operational efficiency through integrated clinical pathways that demonstrate a connected approach from early detection through treatment.

Attendees will include health ministers, government strategists, chief executive officers, international investors, and influential figures from artificial intelligence, digital health, and academic institutions.

Within the context of AI and automation, these leaders anticipate emerging technologies, design future workflows, and guide laboratories toward digital maturity through strategic vision.

Health authorities expect the vaccination programme to commence in 2026, marking a significant expansion of the country’s cervical cancer prevention efforts.

It encompasses the capacity to develop, manufacture, and discover through strong partnerships among government, academia, industry, and regulatory bodies.

The collaboration enables Sidra Medicine to connect Builders VC’s expertise and extensive network with their clinical teams, patient populations, and technological platforms.

The facility houses sophisticated laser systems, high-resolution imaging technology for examining the retina and optic nerve, and fully equipped operating theaters that adhere to the most stringent safety and quality standards.

The partnership will equip hospitals and healthcare providers with cutting-edge, high-quality interventional cardiac solutions designed to meet the growing demand for advanced cardiovascular care.

The Lassa Fever E2E Access Roadmap establishes a comprehensive, regionally driven approach that connects every critical stage in transitioning a vaccine from development to sustained, widespread use.

The partnership builds on a Memorandum of Collaboration signed last year under the Global Oncology Initiative, which set the foundation for comprehensive cancer management improvements at the regional referral facility.